Immunization to prevent COVID-19 infection COVID-19, vaccination, BNT162b2, adolescent, liver transplant, immunogenicity, safety
Conditions
Interventions
BNT162b2 vaccine*2,BNT162b2 vaccine*2
Active Comparator Drug,Active Comparator Drug
Immunocompromised children,Healthy volunteer
Sponsors
Chulalongkorn university
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: Children aged 12-18 years who underwent liver transplant for more than 6 months, clinical stable condition, no history of COVID-19 infection, no history of drug or vaccine allergy
Exclusion criteria
Exclusion criteria: Unstable condition, no willing to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety At day 0-7 after dose 1 and 2 adverse events,IgG to receptor binding site At the beginning of the study, day 21, day 35 and day 51 BAU/mL,IgG to nucleocapsid antigen At the beginning, day 21, day 35 and day 51 %,neutralizing antibody At the beginning, day 21, day 35 and day 51 %,IFN-gamma At the beginning, day 21, day 35 and day 51 SFU/10 million PBMCs | — |
Secondary
| Measure | Time frame |
|---|---|
| Factor related immune response At the end of the study factors | — |
Countries
Thailand
Contacts
Public ContactPalittiya Sintusek
Chulalongkorn University
Outcome results
None listed